Characteristics of pancreatic β-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide

Diabetes Research and Clinical Practice

Volumn 52, Issue 2, 2001, Pages 103-111

  Van der Wal, P S ^a,c   Heine, R J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Res Inst Endocrinol   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Diabetic; Glibenclamide; Gliclazide; Type 2

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; PROINSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; REFERENCE VALUES; SULFONYLUREA COMPOUNDS;

EID: 0035055254     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00242-4     Document Type: Article

References (19)

1. Oral hypoglycaetnic agents
2. Sulphonylureas in NIDDM
3. Do adipocytes contain high affinity sulphonylurea receptors
4. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function
5. Effect of acute administration of gliclazide on the glucose sensitivity of pancreatic B-cells in healthy subjects
6. The mode of action and clinical pharmacology of gliclazide: a review
7. The triumvirate: β-cell, muscle, liver
8. Effect of loss if first phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans
9. Effects of gliclazide on insulin secretion induced by glucose and amino acids
10. The relationship between first-phase insulin secretion and glucose metabolism
11. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational terapeutic use
12. Glucose clamp technique: a method for quantifying insulin secretion and resistance
13. Use of heated superficial hand vein as alternative site for the measurement of aminoacid concentrations and for the study of glucose and alanine kinetics
14. Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man
15. PKC-dependent stimulation of exocytosis by sulphonylureas in pancreatic β-cells
16. Glibenclamide is exceptional among hypoglycaemic agents in accumulating progressively in B-cell rich pancreatic islets
17. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics
18. Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects
19. Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in Type 2 diabetes decreases following sulphonylurea treatment